274656
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 12
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -5.004925498
- umap2_2d
- 2.092294967
- umap1_3d
- -0.767887744
- umap2_3d
- 3.921538571
- umap3_3d
- -1.152140042
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.460
- PROTEIN_SECRETION+0.390
- MITOTIC_SPINDLE+0.360
- MTORC1_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.290
- MYC_TARGETS_V2+0.280
- DNA_REPAIR+0.230
- ANDROGEN_RESPONSE+0.180
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.340
- PANCREAS_BETA_CELLS-0.250
- KRAS_SIGNALING_DN-0.230
- NOTCH_SIGNALING-0.230
- ESTROGEN_RESPONSE_EARLY-0.220
- P53_PATHWAY-0.220
- BILE_ACID_METABOLISM-0.200
- APICAL_SURFACE-0.190
- ESTROGEN_RESPONSE_LATE-0.180
- APICAL_JUNCTION-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | HLF_LIVER | HCC | — | 0.836 |
| 2 | SRR8943045 | — | — | 0.805 |
| 3 | SRR934804 | — | — | 0.805 |
| 4 | SRR8518311 | — | E | 0.803 |
| 5 | TCGA-78-7146-01A-11R-2039-07 | — | cohortA1 | 0.802 |
| 6 | SRR4195653 | — | — | 0.797 |
| 7 | TCGA-05-4415-01A-22R-1858-07 | — | cohortA4 | 0.797 |
| 8 | MDT-AP-2180 | Med | Medulloblastoma | 0.795 |
| 9 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.790 |
| 10 | R392 | — | — | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |